Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

20 janv. 2026 09h17 HE | Source: Spherix Global Insights

Rheumatologists Sharpen Differentiation Across the SLE Pipeline as Late-Stage Assets Crystallize into More Defined Clinical Roles, According to Spherix Global Insights

Exton, PA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Updated findings from the Q4 2025 Market Dynamix™: SLE, Pipeline Refresh reveal a maturing and increasingly stratified development landscape, as US...
20 janv. 2026 09h00 HE | Source: BioAge Labs, Inc.

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and...
20 janv. 2026 08h00 HE | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Announces First Patients Randomized in SGP-005 and SGP-006, Two Registrational Phase III Clinical Trials of Its Novel BIM-IOL System

ALISO VIEJO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational...
20 janv. 2026 01h30 HE | Source: NICOX SA

Nicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiques

Communiqué de presseNicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiques20 janvier 2026 – publication à 7H30Sophia Antipolis,...
20 janv. 2026 01h30 HE | Source: NICOX SA

Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations

Press Release Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data PresentationsJanuary 20, 2026 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth...
19 janv. 2026 09h00 HE | Source: BVI Medical, Inc.

BVI Appoints Jim Hollingshead as President & Chief Executive Officer

BVI appoints Jim Hollingshead as President & CEO, succeeding Shervin Korangy, to lead the company’s next phase of global growth and innovation.
16 janv. 2026 08h49 HE | Source: CMI

Vision Care Market Size to Surpass USD 169.38 Billion by 2032, Driven by Rising Vision Disorders | Coherent Market Insights

Burlingame, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The Global Vision Care Market is estimated to be valued at USD 104.11 Bn in 2025 and is expected to reach USD 169.38 Bn by 2032, exhibiting a...
15 janv. 2026 16h05 HE | Source: PainReform Ltd

PainReform Ltd. Changes Name to PRF Technologies Ltd. Reflecting Expansion into Diversified Healthcare and AI-Driven Energy Platforms

TEL AVIV, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) (formerly “PainReform”) today announced its corporate name change to PRF...
15 janv. 2026 10h38 HE | Source: Research and Markets

Uveitis Global Clinical Trials Review Report 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status

Dublin, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The "Uveitis - Global Clinical Trials Review, 2025" report has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an...
15 janv. 2026 08h15 HE | Source: Ocugen

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2...

Page précédente

Page suivante